Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 737-744

  Veldt, B J ^a,b   Duarte Rojo, A ^a   Thompson, A J ^c   Watt, K D ^a   Heimbach, J K ^a   Tillmann, H L ^c   Goldstein, D D ^c   McHutchison, J G ^c   Charlton, M R ^a  

^a MAYO CLINIC   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; HCV; liver transplantation

Indexed keywords

CHOLESTEROL; DNA; GLUCOSE; JANUS KINASE; STAT PROTEIN;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GENE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; IL28B GENE; INSULIN RESISTANCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 84857645335     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03843.x     Document Type: Article

References (31)

1. Bode JG, Ludwig S, Ehrhardt C, et al,. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488-490.
2. Kubo M, Hanada T, Yoshimura A,. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4: 1169-1176. (Pubitemid 37540685)
3. Persico M, Capasso M, Persico E, et al,. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007; 46: 1009-1015. (Pubitemid 350144765)
4. Ueki K, Kondo T, Kahn CR,. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004; 24: 5434-5446. (Pubitemid 38738176)
5. Veldt BJ, Chen W, Heathcote EJ, et al,. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862. (Pubitemid 351945553)
6. Veldt BJ, Poterucha JJ, Watt KD, et al,. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009; 9: 1406-1413.
7. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, et al,. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-727.
8. Thompson AJ, Muir AJ, Sulkowski MS, et al,. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.e18.
9. Maher SG, Sheikh F, Scarzello AJ, et al,. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-1115.
10. Expert Committee on the Diagnosis and Classification of Diabetes. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 (Suppl 1): S5-S10.
11. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Abdullah A, Peeters A, de Courten M, Stoelwinder J,. The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2010; 89: 309-319.
13. Charlton M,. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl 2009; 15 (Suppl 2): S83-S89.
14. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
15. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA,. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 2004; 10: 349-355. (Pubitemid 38380307)
16. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G,. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-627. (Pubitemid 24066891)
17. Kawaguchi T, Yoshida T, Harada M, et al,. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508. (Pubitemid 39435150)
18. Delgado-Borrego A, Jordan SH, Negre B, et al,. Reduction of insulin resistance with effective clearance of hepatitis C infection: Results from the HALT-C trial. Clin Gastroenterol Hepatol 2010; 8: 458-462.
19. Suppiah V, Moldovan M, Ahlenstiel G, et al,. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
20. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
21. Honda M, Sakai A, Yamashita T, et al,. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
22. Urban TJ, Thompson AJ, Bradrick SS, et al,. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
23. Feld J, Chen L, Liu X, et al,. Hepatic gene expression profile is a better predictor of treatment outcome in HCV infection than IL28b genotype. Hepatology 2010; 52 (Suppl): 391A.
24. Dill MT, Duong FH, Vogt JE, et al,. Interferon-Induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
25. Kim KA, Lin W, Tai AW, et al,. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 2009; 50: 705-711.
26. Huang Y, Feld JJ, Sapp RK, et al,. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132: 733-744. (Pubitemid 46274665)
27. Pazienza V, Clement S, Pugnale P, et al,. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171. (Pubitemid 46775778)
28. Vanni E, Abate ML, Gentilcore E, et al,. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009; 50: 697-706.
29. Taniguchi CM, Emanuelli B, Kahn CR,. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96. (Pubitemid 43278292)
30. El-Serag HB, Richardson PA, Everhart JE,. The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-2467. (Pubitemid 32769212)
31. Foxton MR, Quaglia A, Muiesan P, et al,. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006; 6: 1922-1929. (Pubitemid 44024965)